Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?
作者信息
Vasey P A, Kaye S B
出版信息
Br J Cancer. 1997;76(11):1395-7. doi: 10.1038/bjc.1997.568.
Abstract
摘要
相似文献
1
Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?
Br J Cancer. 1997;76(11):1395-7. doi: 10.1038/bjc.1997.568.
2
Clinical use of topoisomerase I inhibitors in anticancer treatment.
Med Pediatr Oncol. 2000 Oct;35(4):385-402. doi: 10.1002/1096-911x(20001001)35:4<385::aid-mpo1>3.0.co;2-e.
3
Phase I clinical trial of weekly combined topotecan and irinotecan.
Am J Clin Oncol. 2001 Aug;24(4):336-40. doi: 10.1097/00000421-200108000-00003.
4
The development of camptothecin analogs in childhood cancers.
Oncologist. 2001;6(6):506-16. doi: 10.1634/theoncologist.6-6-506.
5
Clinical development of topoisomerase-interactive drugs.
Adv Pharmacol. 1994;29B:1-31. doi: 10.1016/s1054-3589(08)61129-1.
6
Commentary: topoisomerases as targets in acute leukemia: I, II, I plus II or none?
Leuk Res. 2003 Jan;27(1):1-3. doi: 10.1016/s0145-2126(02)00219-9.
7
An overview of topoisomerase I-targeting agents.
Semin Hematol. 1998 Jul;35(3 Suppl 4):3-12.
8
The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies.
Cancer Treat Rev. 1998 Jun;24(3):205-20. doi: 10.1016/s0305-7372(98)90050-0.
9
A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer.
Breast Cancer Res Treat. 2013 Apr;138(2):347-58. doi: 10.1007/s10549-013-2476-3. Epub 2013 Mar 20.
10
Colorectal cancer chemotherapy: irinotecan.
Semin Oncol. 2000 Oct;27(5 Suppl 10):138-43.
引用本文的文献
1
Efficiency of Protective Interventions on Irinotecan-Induced Diarrhea: A Systematic Review and Meta-Analysis.
Integr Cancer Ther. 2024 Jan-Dec;23:15347354241242110. doi: 10.1177/15347354241242110.
2
Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview.
Int J Mol Sci. 2020 Jul 12;21(14):4919. doi: 10.3390/ijms21144919.
3
Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan.
Drug Des Devel Ther. 2009 Sep 21;3:213-7. doi: 10.2147/dddt.s6423.
4
Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer.
Br J Cancer. 2004 Aug 16;91(4):659-65. doi: 10.1038/sj.bjc.6602056.
5
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer.
Invest New Drugs. 2003 Aug;21(3):347-52. doi: 10.1023/a:1025476813365.
6
Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours.
Br J Cancer. 2003 Aug 18;89(4):617-24. doi: 10.1038/sj.bjc.6601147.
7
Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507.
Br J Cancer. 2003 Mar 24;88(6):808-13. doi: 10.1038/sj.bjc.6600800.
本文引用的文献
1
Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer.
J Clin Oncol. 1997 Jan;15(1):304-9. doi: 10.1200/JCO.1997.15.1.304.
2
Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.
J Clin Oncol. 1996 Oct;14(10):2785-90. doi: 10.1200/JCO.1996.14.10.2785.
3
Current perspectives on camptothecins in cancer treatment.
Br J Cancer. 1996 Aug;74(3):327-38. doi: 10.1038/bjc.1996.362.
4
DNA topoisomerase I and II in cancer chemotherapy: update and perspectives.
Cancer Chemother Pharmacol. 1993;32(2):103-8. doi: 10.1007/BF00685611.
5
Phase I study of CPT-11 and etoposide in patients with refractory solid tumors.
J Clin Oncol. 1993 Oct;11(10):2030-5. doi: 10.1200/JCO.1993.11.10.2030.
6
Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
J Clin Oncol. 1994 Sep;12(9):1833-41. doi: 10.1200/JCO.1994.12.9.1833.
7
Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II.
Science. 1984 Oct 26;226(4673):466-8. doi: 10.1126/science.6093249.
8
Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II.
J Biol Chem. 1984 Jul 25;259(14):9182-7.
9
Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer.
Cancer Chemother Rep. 1972 Feb;56(1):95-101.
10
Treatment of malignant melanoma with camptothecin (NSC-100880).
Cancer Chemother Rep. 1972 Feb;56(1):103-5.
Zotero 插件